vs
SAUL CENTERS, INC.（BFS）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是SAUL CENTERS, INC.的1.2倍（$92.9M vs $75.1M），Vericel Corp净利率更高（25.0% vs 8.7%，领先16.4%），Vericel Corp同比增速更快（23.3% vs 10.6%），过去两年Vericel Corp的营收复合增速更高（34.6% vs 6.2%）
Saul Centers, Inc.是一家总部位于美国的自主运营房地产投资信托，主要持有、运营及开发优质购物中心、混合用途物业与多户住宅资产，核心资产组合集中在华盛顿大都会区及美国其他精选高增长区域市场。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
BFS vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.2倍
$75.1M
营收增速更快
VCEL
高出12.6%
10.6%
净利率更高
VCEL
高出16.4%
8.7%
两年增速更快
VCEL
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $92.9M |
| 净利润 | $6.5M | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 65.4% | 24.1% |
| 净利率 | 8.7% | 25.0% |
| 营收同比 | 10.6% | 23.3% |
| 净利润同比 | -19.6% | 17.3% |
| 每股收益（稀释后） | $0.15 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFSVCEL
| Q4 25 | $75.1M | $92.9M | ||
| Q3 25 | $72.0M | $67.5M | ||
| Q2 25 | $70.8M | $63.2M | ||
| Q1 25 | $71.9M | $52.6M | ||
| Q4 24 | $67.9M | $75.4M | ||
| Q3 24 | $67.3M | $57.9M | ||
| Q2 24 | $66.9M | $52.7M | ||
| Q1 24 | $66.7M | $51.3M |
净利润BFSVCEL
| Q4 25 | $6.5M | $23.2M | ||
| Q3 25 | $10.5M | $5.1M | ||
| Q2 25 | $10.7M | $-553.0K | ||
| Q1 25 | $9.8M | $-11.2M | ||
| Q4 24 | $8.1M | $19.8M | ||
| Q3 24 | $14.5M | $-901.0K | ||
| Q2 24 | $14.4M | $-4.7M | ||
| Q1 24 | $13.6M | $-3.9M |
毛利率BFSVCEL
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | 73.6% | 71.9% | ||
| Q2 24 | 74.2% | 69.5% | ||
| Q1 24 | 72.8% | 68.9% |
营业利润率BFSVCEL
| Q4 25 | 65.4% | 24.1% | ||
| Q3 25 | 69.1% | 5.1% | ||
| Q2 25 | 68.7% | -3.2% | ||
| Q1 25 | 66.5% | -24.3% | ||
| Q4 24 | 82.9% | 24.5% | ||
| Q3 24 | 72.8% | -4.3% | ||
| Q2 24 | 75.0% | -11.5% | ||
| Q1 24 | 72.4% | -10.7% |
净利率BFSVCEL
| Q4 25 | 8.7% | 25.0% | ||
| Q3 25 | 14.6% | 7.5% | ||
| Q2 25 | 15.1% | -0.9% | ||
| Q1 25 | 13.6% | -21.4% | ||
| Q4 24 | 11.9% | 26.3% | ||
| Q3 24 | 21.5% | -1.6% | ||
| Q2 24 | 21.6% | -8.9% | ||
| Q1 24 | 20.4% | -7.5% |
每股收益（稀释后）BFSVCEL
| Q4 25 | $0.15 | $0.46 | ||
| Q3 25 | $0.32 | $0.10 | ||
| Q2 25 | $0.33 | $-0.01 | ||
| Q1 25 | $0.29 | $-0.23 | ||
| Q4 24 | $0.22 | $0.40 | ||
| Q3 24 | $0.48 | $-0.02 | ||
| Q2 24 | $0.48 | $-0.10 | ||
| Q1 24 | $0.45 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.7M | $137.5M |
| 总债务越低越好 | $468.4M | — |
| 股东权益账面价值 | $307.8M | $354.6M |
| 总资产 | $2.2B | $488.0M |
| 负债/权益比越低杠杆越低 | 1.52× | — |
8季度趋势，按日历期对齐
现金及短期投资BFSVCEL
| Q4 25 | $8.7M | $137.5M | ||
| Q3 25 | $11.8M | $135.4M | ||
| Q2 25 | $5.3M | $116.9M | ||
| Q1 25 | $6.5M | $112.9M | ||
| Q4 24 | $10.3M | $116.2M | ||
| Q3 24 | $7.2M | $101.7M | ||
| Q2 24 | $6.9M | $102.5M | ||
| Q1 24 | $7.1M | $110.6M |
总债务BFSVCEL
| Q4 25 | $468.4M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $455.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益BFSVCEL
| Q4 25 | $307.8M | $354.6M | ||
| Q3 25 | $316.6M | $321.9M | ||
| Q2 25 | $322.4M | $306.8M | ||
| Q1 25 | $328.4M | $295.5M | ||
| Q4 24 | $335.8M | $292.0M | ||
| Q3 24 | $341.8M | $257.5M | ||
| Q2 24 | $345.7M | $243.0M | ||
| Q1 24 | $347.1M | $233.9M |
总资产BFSVCEL
| Q4 25 | $2.2B | $488.0M | ||
| Q3 25 | $2.2B | $453.3M | ||
| Q2 25 | $2.1B | $435.6M | ||
| Q1 25 | $2.1B | $424.6M | ||
| Q4 24 | $2.1B | $432.7M | ||
| Q3 24 | $2.1B | $390.4M | ||
| Q2 24 | $2.1B | $376.8M | ||
| Q1 24 | $2.0B | $356.7M |
负债/权益比BFSVCEL
| Q4 25 | 1.52× | — | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.8M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | — | $12.8M |
| 自由现金流率自由现金流/营收 | — | 13.8% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | 15.35× | 0.65× |
| 过去12个月自由现金流最近4个季度 | — | $24.7M |
8季度趋势，按日历期对齐
经营现金流BFSVCEL
| Q4 25 | $99.8M | $15.0M | ||
| Q3 25 | $20.6M | $22.1M | ||
| Q2 25 | $26.6M | $8.2M | ||
| Q1 25 | $30.4M | $6.6M | ||
| Q4 24 | $121.2M | $22.2M | ||
| Q3 24 | $26.5M | $10.2M | ||
| Q2 24 | $32.1M | $18.5M | ||
| Q1 24 | $33.8M | $7.2M |
自由现金流BFSVCEL
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $-28.3M | $-9.2M | ||
| Q2 24 | $-12.5M | $1.8M | ||
| Q1 24 | $-11.7M | $-6.8M |
自由现金流率BFSVCEL
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | -42.1% | -15.9% | ||
| Q2 24 | -18.7% | 3.4% | ||
| Q1 24 | -17.6% | -13.3% |
资本支出强度BFSVCEL
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | 81.5% | 33.5% | ||
| Q2 24 | 66.7% | 31.8% | ||
| Q1 24 | 68.3% | 27.3% |
现金转化率BFSVCEL
| Q4 25 | 15.35× | 0.65× | ||
| Q3 25 | 1.97× | 4.35× | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | 1.12× | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BFS
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
